Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott received CE Mark approval for Alinity HQ haematology analyser

Abbott received CE Mark approval for Alinity HQ haematology analyser

21st June 2017

Abbott has announced the European launch of its new Alinity HQ analyser for haematology, having received CE Mark approval for the device.

The analyser is the first in the Alinity haematology series of instruments to be commercially released, and allows users to conduct tests to examine various aspects of blood composition, including the identification and quantification of different types of blood cells.

Abbott's device automates the performance of these tests and reports on 29 different parameters within minutes, while its design helps to reduce manual steps and minimise errors.

Additionally, it features the same iconography, colour coding and reporting features as other Alinity instruments and the same approach to sample loading and reagent management, thereby helping to simplify technician training processes.

Luis de Luzuriaga, divisional vice-president and general manager for Abbott's haematology business, said: "With the Alinity family of harmonised systems, Abbott aims to simplify diagnostics testing across laboratory disciplines and help our customers improve patient outcomes."

This launch comes as part of a broader suite of planned integrated haematology solutions designed to address productivity needs in high-volume laboratories.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837088-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.